You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials

Article metrics

Article menu
Epidemiology and outcomes
Original research
Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials

 

Online download statistics by month:

Online download statistics by month: October 2021 to March 2024

AbstractFullPdf
Oct 202123823653
Nov 2021337332116
Dec 202120019863
Jan 20229510256
Feb 2022737224
Mar 2022656530
Apr 2022969648
May 202210110146
Jun 202211311539
Jul 2022787620
Aug 202210110027
Sep 2022928840
Oct 202211010962
Nov 2022647039
Dec 2022696932
Jan 2023727028
Feb 202311010640
Mar 2023727333
Apr 2023838341
May 2023969152
Jun 2023666439
Jul 2023525129
Aug 2023757118
Sep 2023605915
Oct 202368669
Nov 2023757223
Dec 2023474411
Jan 2024403118
Feb 2024433835
Mar 2024555423
Total284628021109